# Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer

> **NCT00100815** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 50 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** capecitabine
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00100815
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2008-08
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2015-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00100815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00100815, "Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00100815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*